阿达木单抗
英夫利昔单抗
医学
免疫学
肿瘤坏死因子α
银屑病
银屑病性关节炎
类风湿性关节炎
免疫系统
强直性脊柱炎
炎症性肠病
关节炎
先天免疫系统
细胞因子
疾病
内科学
作者
Léia C R Silva,Luciena Cegatto Martins Ortigosa,Gil Benard
出处
期刊:Immunotherapy
[Future Medicine]
日期:2010-11-01
卷期号:2 (6): 817-833
被引量:189
摘要
TNF-α is a potent inducer of the inflammatory response, a key regulator of innate immunity and plays an important role in the regulation of Th1 immune responses against intracellular bacteria and certain viral infections. However, dysregulated TNF can also contribute to numerous pathological situations. These include immune-mediated inflammatory diseases (IMIDs) including rheumatoid arthritis, Crohn's disease, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis and severe chronic plaque psoriasis. Animal and human studies concerning the role of TNF-α in IMIDs have led to the development of a therapy based on TNF blockage. This article focuses first on the potential mechanisms by which the three currently licensed agents, adalimumab, etarnecept and infliximab, decrease the inflammatory activity of patients with different IMIDs. Second, it focuses on the risks, precautions and complications of the use of TNF-α inhibitors in these patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI